173 related articles for article (PubMed ID: 36682299)
1. Diosgenin attenuates non-alcoholic fatty liver disease in type 2 diabetes through regulating SIRT6-related fatty acid uptake.
Nie K; Gao Y; Chen S; Wang Z; Wang H; Tang Y; Su H; Lu F; Dong H; Fang K
Phytomedicine; 2023 Mar; 111():154661. PubMed ID: 36682299
[TBL] [Abstract][Full Text] [Related]
2. Diosgenin protects against podocyte injury in early phase of diabetic nephropathy through regulating SIRT6.
Wang Z; Wu Q; Wang H; Gao Y; Nie K; Tang Y; Su H; Hu M; Gong J; Fang K; Dong H
Phytomedicine; 2022 Sep; 104():154276. PubMed ID: 35728388
[TBL] [Abstract][Full Text] [Related]
3. [Diosgenin alleviates NAFLD induced by a high-fat diet in rats via mTOR/SREBP-1c/HSP60/MCAD/SCAD signaling pathway].
Chen SW; Yin GL; Song CY; Meng DC; Yu WF; Zhang X; Feng YN; Liang PP; Zhang FX
Zhongguo Zhong Yao Za Zhi; 2023 Oct; 48(19):5304-5314. PubMed ID: 38114120
[TBL] [Abstract][Full Text] [Related]
4. [Effect of diosgenin on mTOR/FASN/HIF-1α/VEGFA expression in rats with non-alcoholic fatty liver disease].
Yin GL; Liang HY; Liang PP; Feng YN; Chen SW; Liu XY; Pan WC; Zhang FX
Zhongguo Zhong Yao Za Zhi; 2023 Apr; 48(7):1760-1769. PubMed ID: 37282950
[TBL] [Abstract][Full Text] [Related]
5. Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease.
Zhou M; Liu X; Wu Y; Xiang Q; Yu R
J Ethnopharmacol; 2024 Jul; 329():118160. PubMed ID: 38588985
[TBL] [Abstract][Full Text] [Related]
6. [Zuogui Jiangtang Qinggan Formula improves glucolipid metabolism in type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease by regulating FoxO1/MTP/APOB signaling pathway].
Xiang YX; Huang YL; Zhou M; Zou JJ; Liu X; Liu ZY; Xiao F; Yu R; Xiang Q
Zhongguo Zhong Yao Za Zhi; 2023 Aug; 48(16):4438-4445. PubMed ID: 37802870
[TBL] [Abstract][Full Text] [Related]
7. Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells.
Fang K; Wu F; Chen G; Dong H; Li J; Zhao Y; Xu L; Zou X; Lu F
BMC Complement Altern Med; 2019 Sep; 19(1):255. PubMed ID: 31519174
[TBL] [Abstract][Full Text] [Related]
8. Cytoplasmic SIRT6-mediated ACSL5 deacetylation impedes nonalcoholic fatty liver disease by facilitating hepatic fatty acid oxidation.
Hou T; Tian Y; Cao Z; Zhang J; Feng T; Tao W; Sun H; Wen H; Lu X; Zhu Q; Li M; Lu X; Liu B; Zhao Y; Yang Y; Zhu WG
Mol Cell; 2022 Nov; 82(21):4099-4115.e9. PubMed ID: 36208627
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
[TBL] [Abstract][Full Text] [Related]
10. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
Lee MR; Yang HJ; Park KI; Ma JY
Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
[TBL] [Abstract][Full Text] [Related]
11. Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats.
Zhong Y; Li Z; Jin R; Yao Y; He S; Lei M; Wang X; Shi C; Gao L; Peng X
Nutrients; 2022 Nov; 14(23):. PubMed ID: 36501024
[TBL] [Abstract][Full Text] [Related]
12. Diosgenin as a substitute for cholesterol alleviates NAFLD by affecting CYP7A1 and NPC1L1-related pathway.
Yan M; Zhao Y; Man S; Dai Y; Ma L; Gao W
Phytomedicine; 2024 Mar; 125():155299. PubMed ID: 38301301
[TBL] [Abstract][Full Text] [Related]
13. SIRT6: therapeutic target for nonalcoholic fatty liver disease.
Zang M; Gao B
Trends Endocrinol Metab; 2022 Dec; 33(12):801-803. PubMed ID: 36328906
[TBL] [Abstract][Full Text] [Related]
14. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
Zhang J; Du H; Shen M; Zhao Z; Ye X
J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
[TBL] [Abstract][Full Text] [Related]
15. Regulation of Hepatocellular Fatty Acid Uptake in Mouse Models of Fatty Liver Disease with and without Functional Leptin Signaling: Roles of NfKB and SREBP-1C and the Effects of Spexin.
Ge JF; Walewski JL; Anglade D; Berk PD
Semin Liver Dis; 2016 Sep; 36(4):360-372. PubMed ID: 27997977
[TBL] [Abstract][Full Text] [Related]
16. Targeting mTOR/YY1 signaling pathway by quercetin through CYP7A1-mediated cholesterol-to-bile acids conversion alleviated type 2 diabetes mellitus induced hepatic lipid accumulation.
Yang T; Wang Y; Cao X; Peng Y; Huang J; Chen L; Pang J; Jiang Z; Qian S; Liu Y; Ying C; Wang T; Zhang F; Lu Q; Yin X
Phytomedicine; 2023 May; 113():154703. PubMed ID: 36889164
[TBL] [Abstract][Full Text] [Related]
17. Schisandrin B ameliorates non-alcoholic liver disease through anti-inflammation activation in diabetic mice.
Ma R; Zhan Y; Zhang Y; Wu L; Wang X; Guo M
Drug Dev Res; 2022 May; 83(3):735-744. PubMed ID: 34927282
[TBL] [Abstract][Full Text] [Related]
18. GB1a Activates SIRT6 to Regulate Lipid Metabolism in Mouse Primary Hepatocytes.
Sun Y; Zheng C; Li T; He X; Yang F; Guo W; Song J; Gao Y; Deng C; Huang X
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298491
[TBL] [Abstract][Full Text] [Related]
19. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.
Yang JM; Sun Y; Wang M; Zhang XL; Zhang SJ; Gao YS; Chen L; Wu MY; Zhou L; Zhou YM; Wang Y; Zheng FJ; Li YH
World J Gastroenterol; 2019 Sep; 25(34):5105-5119. PubMed ID: 31558860
[TBL] [Abstract][Full Text] [Related]
20. Sirtuin 6-A Key Regulator of Hepatic Lipid Metabolism and Liver Health.
Dong XC
Cells; 2023 Feb; 12(4):. PubMed ID: 36831330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
